Lilly Sets Dates and Conference Calls for 2015 Financial Guidance and Fourth-Quarter 2014 Financial Results

INDIANAPOLIS, Dec. 17, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial guidance for 2015 on Wednesday, January 7, 2015 and, separately, will announce its financial results for the fourth quarter and full year of 2014 on Friday, January 30, 2015.  On each day, Lilly will also conduct conference calls with the investment community and media to further detail the company's 2015 financial guidance and its 2014 financial performance, respectively.

The conference calls on both days will begin at 9:00 a.m. EST.  Investors, media and the general public can access live webcasts of the conference calls through links that will be posted on Lilly's website at www.lilly.com.

About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels.  F-LLY   

Refer to:

(317) 277-6524; [email protected]; Lauren Zierke (Media)


(317) 655-6874; [email protected]; Phil Johnson (Investor)

 

Eli Lilly and Company logo.

Logo - http://photos.prnewswire.com/prnh/20031219/LLYLOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/lilly-sets-dates-and-conference-calls-for-2015-financial-guidance-and-fourth-quarter-2014-financial-results-300011255.html

SOURCE Eli Lilly and Company

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.